---
title: "Bezuclastinib in Gastrointestinal stromal tumor: Clinical evidence"
description: "Formulary evidence on Bezuclastinib in Gastrointestinal stromal tumor: Clinical evidence. Covers PEAK, SARC044, INTRIGUE, A6181004, 05-177, and PLX121-01. 118 evidence topics quoted from 30 sources."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib in Gastrointestinal stromal tumor: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 PEAK

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Randomized comparison after prior imatinib

> “To determine the efficacy of bezuclastinib and sunitinib vs sunitinib in patients with GIST and prior imatinib only”

Source: [Cogent Biosciences ASCO poster (2023)](https://www.cogentbio.com/wp-content/uploads/2023/06/CogentBio_ASCO-2023-Peak.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study initiation

> “study started April 2022”

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)

<a id="topic-3.1.1.2-2"></a>

###### Part 1 update cutoff

> “April 1, 2024”

Source: [Cogent Biosciences (2024)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-updated-lead-data-ongoing)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Open-label international study and randomization

> “open-label, international, multicenter study”
> “patients being randomized in a 1:1 manner.”

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)

<a id="topic-3.1.1.3-2"></a>

###### Crossover after centrally confirmed progression

> “Crossover allowed following BICR confirmed PD”

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de)

Additional sources: [Tap et al. (2024)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS11588); [Heinrich et al. (2024b)](https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.TPS766)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Histologic diagnosis and disease extent

> “Histologically confirmed locally advanced, metastatic, and/or unresectable GIST.”

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)

<a id="topic-3.1.1.4-2"></a>

###### Prior therapy for the randomized comparison

> “Prior treatment with imatinib only”

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)

<a id="topic-3.1.1.4-3"></a>

###### Excluded molecular subtypes

> “Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency”

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Selected combination dose

> “bezuclastinib 600 mg QD + sunitinib 37.5 mg QD”

Source: [Wagner et al. (2024a)](https://www.cogentbio.com/wp-content/uploads/ASCO-2024-Peak-Part-1.pdf)

<a id="topic-3.1.1.5-2"></a>

###### Control-arm daily dose

| Treatment | Daily dose, mg |
| --- | --- |
| Sunitinib | “37.5” |

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using BICR-assessed Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary and key secondary endpoints

| Endpoint role | Endpoint |
| --- | --- |
| Primary | “Progression Free Survival per BICR” |
| Key secondary | “Objective Response Rate per BICR” |
| Key secondary | “Overall Survival” |

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de)

<a id="topic-3.1.1.6.1-2"></a>

###### Regulatory context for progression-free survival

> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit.”
> “Its determination is not confounded by subsequent therapy.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment in the randomized part

> “approximately 388 patients”

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)

<a id="topic-3.1.1.7.1-2"></a>

###### Pivotal randomized population

> “413 patients with advanced GIST who had received prior therapy with imatinib were randomized to either bezuclastinib plus sunitinib or sunitinib alone.”

Source: [Dana-Farber Cancer Institute (2026)](https://www.newswise.com/articles/dana-farber-researchers-to-present-two-plenary-studies-and-additional-late-breaking-cancer-research-at-2026-asco)

<a id="topic-3.1.1.7.1-3"></a>

###### Part 1 treated population

| Population | Participants |
| --- | --- |
| Part 1 | “42” |

Source: [Wagner et al. (2024a)](https://www.cogentbio.com/wp-content/uploads/ASCO-2024-Peak-Part-1.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Summary

The pivotal response analysis reports 204 participants assigned to the combination and 209 assigned to sunitinib. The safety presentation uses 204 and 208 participants, respectively. These denominators should not be interchanged.

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de)

<a id="topic-3.1.1.7.2-2"></a>

###### Part 1 safety analysis set

> “Safety Analysis Set: All treated pts”

Source: [Wagner et al. (2024a)](https://www.cogentbio.com/wp-content/uploads/ASCO-2024-Peak-Part-1.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Randomized-part safety population

| Treatment | Participants |
| --- | --- |
| Bezuclastinib plus sunitinib | “204” |
| Sunitinib | “208” |

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de)

<a id="topic-3.1.1.7.2-4"></a>

###### Full statistical analysis plan

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Summary

One participant assigned to sunitinib did not receive treatment. In the Part 1 update, 31 of 42 participants had discontinued and 11 remained on study treatment.

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de); [Wagner et al. (2024a)](https://www.cogentbio.com/wp-content/uploads/ASCO-2024-Peak-Part-1.pdf)

<a id="topic-3.1.1.8.1-2"></a>

###### Part 1 disposition

| Disposition | Participants |
| --- | --- |
| Discontinued | “31” |
| Ongoing | “11” |

Source: [Wagner et al. (2024a)](https://www.cogentbio.com/wp-content/uploads/ASCO-2024-Peak-Part-1.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Pivotal population age

| Characteristic | Value |
| --- | --- |
| Median age and range, years | “63 (30-88)” |

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### PEAK phase 3: progression-free survival

> “mPFS, as assessed by blinded independent central review, was 16.5 months for the bezuclastinib combination vs. 9.2 months for sunitinib monotherapy.”

Source: [Cogent Biosciences GIST new drug application submission initiation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-initiate-new-drug-application-nda-submission)

<a id="topic-3.1.1.8.3-2"></a>

###### Pivotal progression-free-survival treatment effect

> “The combination reached a median progression free survival (mPFS) of 16.5 months compared to sunitinib monotherapy, which reached a mPFS of 9.2 months (HR=0.50, CI: 0.39-0.65; p<0.0001).”

Source: [Cogent Biosciences (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-positive-results-bezuclastinib-peak)

<a id="topic-3.1.1.8.3-3"></a>

###### PEAK phase 3: objective response

| Treatment arm                         | “ORR per BICR , %, n [95% CI]” |
| ------------------------------------- | ------------------------------ |
| “Bezuclastinib + Sunitinib” “(n=204)” | “45.6%” “93 [38.6, 52.7]”      |
| “Sunitinib” “(n=209)”                 | “25.8%” “54 [20.0, 32.3]”      |

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de)

<a id="topic-3.1.1.8.3-4"></a>

###### PEAK phase 3: overall survival

> “Data for overall survival remains immature.”

Source: [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11)

<a id="topic-3.1.1.8.3-5"></a>

###### Progression on subsequent therapy: endpoint definition

> “the time from randomization to progression on the next line of therapy or death.”

Source: [Cogent Biosciences PEAK detailed results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-detailed-clinical-data-peak-phase-3)

<a id="topic-3.1.1.8.3-6"></a>

###### Progression on subsequent therapy: reported results

| Measure | Value |
| --- | --- |
| Combination-arm median, months | “not reached” |
| Sunitinib-arm median, months | “21” |
| Hazard ratio | “0.57” |
| 95% confidence interval | “0.41-0.78” |

Source: [Cogent Biosciences PEAK detailed results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-detailed-clinical-data-peak-phase-3)

<a id="topic-3.1.1.8.3-7"></a>

###### PEAK Part 1: subgroup with one prior treatment

> “median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment”

Source: [Cogent Biosciences (2024)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-updated-lead-data-ongoing)

Additional sources: [Wagner et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11500); [Trent et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.826)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### PEAK phase 3: safety

> “Grade 3+”
> “bezuclastinib combination vs. sunitinib”
> “Hypertension (29.4% vs. 27.4%), Neutropenia (15.2% vs. 15.4%), ALT/AST increased (10.8% vs. 1.4%), Anemia (9.3% vs. 4.8%)”

Source: [Cogent Biosciences (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-positive-results-bezuclastinib-peak)

<a id="topic-3.1.1.8.5-2"></a>

###### PEAK phase 3: treatment discontinuation

> “7.4% of patients on the bezuclastinib combination and 3.8% of patients on sunitinib monotherapy discontinued study treatment(s) due to treatment related adverse events.”

Source: [Cogent Biosciences PEAK detailed results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-detailed-clinical-data-peak-phase-3)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

PEAK was open-label, although progression-free survival was assessed by blinded independent central review. Crossover was permitted after centrally confirmed progression, and overall-survival results remained immature. The randomized comparison required prior imatinib only and excluded PDGFR-driven and succinate dehydrogenase-deficient disease. Part 1 subgroup results should not be treated as randomized estimates.

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047); [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de); [Cogent Biosciences GIST new drug application submission initiation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-initiate-new-drug-application-nda-submission); [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11); [Cogent Biosciences (2024)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-updated-lead-data-ongoing)

<a id="heading-3.1.2"></a>

#### 3.1.2 SARC044

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Safety and efficacy of combination treatment

> “assessing the safety and efficacy of this combination”

Source: [SARC (2025)](https://sarctrials.org/sarc044-completes-enrollment/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Participating U.S. locations

| Location | Reported site location |
| --- | --- |
| Massachusetts | “Boston, MA, USA” |
| Pennsylvania | “Philadelphia, PA, USA” |
| Oregon | “Portland, OR, USA” |
| Florida | “Miami, FL, USA” |

Source: [SARC (2025)](https://sarctrials.org/sarc044-completes-enrollment/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 2 design

> “open label, single arm, phase 2 trial”

Source: [Dana-Farber Cancer Institute SARC044 trial page](https://www.dana-farber.org/clinical-trials/24-195)

Additional sources: [Haddox et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS11579)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Molecular eligibility and prior progression

> “patients with KIT exon 9 or 11-mutant GIST”
> “who have progressed on sunitinib alone.”

Source: [SARC (2025)](https://sarctrials.org/sarc044-completes-enrollment/)

<a id="topic-3.1.2.4-2"></a>

###### Age and performance status

> “Age minimum of 18 years”
> “Performance Status of 0-2”

Source: [Dana-Farber Cancer Institute SARC044 trial page](https://www.dana-farber.org/clinical-trials/24-195)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Bezuclastinib lead-in and added sunitinib

> “bezuclastinib 600 mg daily for 2 weeks”
> “sunitinib 37.5 mg daily”

Source: [Haddox et al. (2024)](https://ctos2024.eventscribe.net/fsPopup.asp?PosterID=691386&mode=posterInfo)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint and planned patient-reported outcome instrument

| Measure | Reported measure |
| --- | --- |
| Primary endpoint | “mPFS” |
| Patient-reported outcome instrument | “EORTC QLQ-C30” |

Source: [Haddox et al. (2024)](https://ctos2024.eventscribe.net/fsPopup.asp?PosterID=691386&mode=posterInfo)

<a id="topic-3.1.2.6.1-2"></a>

###### Regulatory context for progression-free survival

> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.2.6.1-3"></a>

###### Study-specific endpoint justification

No evidence found.

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment and evaluable population

| Population | Participants |
| --- | --- |
| Maximum enrollment | “40” |
| Evaluable population for power calculation | “35” |

Source: [Haddox et al. (2024)](https://ctos2024.eventscribe.net/fsPopup.asp?PosterID=691386&mode=posterInfo)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Summary

The design used a one-sample log-rank calculation with a one-sided 5% significance level. Thirty-five evaluable participants provided 83% power for an assumed median progression-free survival of 6.5 months compared with a 4-month historical benchmark. This is a historical-control calculation, not a randomized comparison.

Source: [Haddox et al. (2024)](https://ctos2024.eventscribe.net/fsPopup.asp?PosterID=691386&mode=posterInfo)

<a id="topic-3.1.2.7.2-2"></a>

###### Statistical planning assumptions

| Parameter | Value |
| --- | --- |
| Statistical test | “one-sample log-rank test” |
| One-sided significance level | “5%” |
| Power | “83%” |
| Assumed median progression-free survival, months | “6.5” |
| Historical-control median progression-free survival, months | “4” |

Source: [Haddox et al. (2024)](https://ctos2024.eventscribe.net/fsPopup.asp?PosterID=691386&mode=posterInfo)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Enrollment completion

> “the successful completion of patient enrollment for SARC044”

Source: [SARC (2025)](https://sarctrials.org/sarc044-completes-enrollment/)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

SARC044 is a single-arm, open-label phase 2 study with planned enrollment of up to 40 participants. Its statistical comparison uses a historical progression-free-survival benchmark rather than a concurrently randomized control. Eligibility primarily specifies KIT exon 9- or 11-mutant GIST, with other primary KIT mutations considered case by case. The enrollment-completion announcement does not establish efficacy or safety results.

Source: [Dana-Farber Cancer Institute SARC044 trial page](https://www.dana-farber.org/clinical-trials/24-195); [Haddox et al. (2024)](https://ctos2024.eventscribe.net/fsPopup.asp?PosterID=691386&mode=posterInfo); [SARC (2025)](https://sarctrials.org/sarc044-completes-enrollment/)

<a id="heading-3.1.3"></a>

#### 3.1.3 INTRIGUE

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Comparative safety and efficacy

> “comparing the safety and efficacy of ripretinib versus sunitinib”

Source: [Nemunaitis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31755321/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### International study sites

| Measure | Number |
| --- | --- |
| Sites | “122” |
| Countries | “22” |

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="topic-3.1.3.2-2"></a>

###### Final overall-survival data cutoff

> “March 15, 2023”

Source: [Heinrich et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12225728/)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Randomized phase 3 design

> “global, randomized (1:1), open-label, Phase III study”

Source: [Nemunaitis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31755321/)

<a id="topic-3.1.3.3-2"></a>

###### Crossover restriction

> “Crossover was not allowed.”

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Prior systemic treatment

> “previously treated with imatinib”

Source: [Heinrich et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12225728/)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Randomized treatment doses

| Treatment | Oral dose |
| --- | --- |
| Ripretinib | “150 mg once daily” |
| Sunitinib | “50 mg once daily” |

Source: [Heinrich et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12225728/)

<a id="topic-3.1.3.5-2"></a>

###### Sunitinib treatment schedule

> “4 weeks on/2 weeks off”

Source: [Heinrich et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12225728/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary and key secondary endpoints

| Endpoint role | Endpoint |
| --- | --- |
| Primary | “progression-free survival” |
| Key secondary | “objective response rate” |
| Key secondary | “overall survival” |

Source: [Nemunaitis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31755321/)

<a id="topic-3.1.3.6.1-2"></a>

###### Regulatory context for progression-free survival

> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Randomized population

> “Overall, 453 patients were randomly assigned”

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Summary

Efficacy analyses used the intention-to-treat population. Safety analyses included participants who received at least one dose. The testing hierarchy evaluated progression-free survival, then response rate, then overall survival, with KIT exon 11 analyses preceding overall-population analyses. Failure of the primary comparison meant subsequent statistical comparisons were not confirmatory.

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="topic-3.1.3.7.2-2"></a>

###### Reported analysis populations

> “ITT population”

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Randomized treatment allocation

| Treatment | Participants |
| --- | --- |
| Ripretinib | “226” |
| Sunitinib | “227” |

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Overall baseline characteristics

| Characteristic | Value |
| --- | --- |
| Median age, years | “60” |
| Male participants, percent | “62.0%” |

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary progression-free-survival comparison

> “Ripretinib was not superior to sunitinib in terms of PFS.”

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="topic-3.1.3.8.3-2"></a>

###### Overall-population progression-free survival

| Measure | Ripretinib | Sunitinib |
| --- | --- | --- |
| Median progression-free survival, months | “8.0” | “8.3” |

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="topic-3.1.3.8.3-3"></a>

###### Final overall-survival analysis

| Comparison | Median overall survival |
| --- | --- |
| Ripretinib versus sunitinib | “35.5 v 31.5 months” |

Source: [Heinrich et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12225728/)

Additional sources: [Heinrich et al. (2024a)](https://www.nature.com/articles/s41591-023-02734-5)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Patient-reported tolerability with ripretinib versus sunitinib

> “better scores on patient-reported outcome measures of tolerability.”

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Grade 3 or 4 treatment-emergent adverse events

| Measure | Ripretinib | Sunitinib |
| --- | --- | --- |
| Participants with events | “41.3%” | “65.6%” |

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The open-label study did not show superiority of ripretinib for its primary progression-free-survival comparison. Safety percentages describe treatment-emergent events and should not be equated with treatment-related-event percentages from other trials. Neither randomized arm contained bezuclastinib.

Source: [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/); [Nemunaitis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31755321/)

<a id="heading-3.1.4"></a>

#### 3.1.4 A6181004

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Anticancer activity assessment

> “anticancer efficacy”

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registry-reported study dates

| Milestone | Date as recorded |
| --- | --- |
| Study start | “1/12/2003” |
| Last data collection | “1/05/2008” |

Source: [ANZCTR NCT00075218](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=418&isClinicalTrial=True)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized and blinded comparison

> “randomised, double-blind, placebo-controlled”

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Minimum age

> “18 Years”

Source: [ANZCTR NCT00075218](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=418&isClinicalTrial=True)

<a id="topic-3.1.4.4-2"></a>

###### Prior treatment requirement

> “Failed Gleevec treatment or intolerant to Gleevec therapy”

Source: [ANZCTR NCT00075218](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=418&isClinicalTrial=True)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Sunitinib once-daily oral starting dose

> “50 mg”

Source: [ANZCTR NCT00075218](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=418&isClinicalTrial=True)

<a id="topic-3.1.4.5-2"></a>

###### Intermittent treatment schedule

> “4 weeks on study drug/2 weeks off study drug.”

Source: [ANZCTR NCT00075218](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=418&isClinicalTrial=True)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Time to Tumor Progression as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary endpoint

> “time to tumour progression”

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="topic-3.1.4.6.1-2"></a>

###### Regulatory distinction between progression and progression-free survival

> “TTP is defined as the time from randomization until objective tumor progression; TTP does not include deaths.”
> “Compared with TTP, PFS is the preferred regulatory endpoint.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Randomized population

| Population | Participants |
| --- | --- |
| Overall | “312” |

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Reported analysis approaches

> “Intention-to-treat”
> “modified intention-to-treat”
> “per-protocol”

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="topic-3.1.4.7.2-2"></a>

###### Detailed analysis-set definitions

> “Analysed study populations included intention-to-treat (ITT; all patients randomised to treatment), modified ITT (all ITT patients with disease progression on imatinib confirmed by central radiology laboratory), and per-protocol (all patients who received at least one dose of assigned study treatment).”
> “ITT data are presented for efficacy and per-protocol data for safety; modified ITT data are discussed where relevant.”

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Summary

The trial was unblinded early after a planned interim analysis showed a longer time to progression with sunitinib.

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="topic-3.1.4.8.1-2"></a>

###### Randomized treatment allocation

| Treatment | Participants |
| --- | --- |
| Sunitinib | “207” |
| Placebo | “105” |

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Balance between randomized groups and prior imatinib exposure

> “Between December, 2003, and January, 2005, 312 patients were enrolled from 56 centres in 11 countries and were randomised to receive blinded sunitinib (n=207) or placebo (n=105).”
> “All characteristics were well balanced between the groups. The most common metastatic sites were the liver, peritoneum, and mesentery.”
> “The sunitinib and placebo groups were also similar in terms of median maximum dose, median daily dose (503 mg vs 485 mg), and median cumulative dose (367 400 mg vs 376 400 mg) of previous imatinib therapy, as well as in other aspects of treatment history.”

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Time to tumor progression

| Measure | Sunitinib | Placebo |
| --- | --- | --- |
| Median, weeks | “27.3” | “6.4” |

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="topic-3.1.4.8.3-2"></a>

###### Treatment effect on time to progression

| Measure | Value |
| --- | --- |
| Hazard ratio | “0.33” |
| P value | “p<0.0001” |

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="topic-3.1.4.8.3-3"></a>

###### Overall survival with crossover permitted

> “Despite the availability of the option to cross over, overall survival obtained with initial sunitinib treatment was better that that obtained with placebo (figure 4; HR 0·49, 95% CI 0·29–0·83; p=0·007)”
> “the trial was unblinded early when a planned interim analysis showed significantly longer time to tumour progression with sunitinib”

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Common treatment-related adverse events

> “fatigue, diarrhoea, skin discolouration, and nausea.”

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The randomized trial was unblinded early after its planned interim analysis. Its primary endpoint was time to tumor progression rather than progression-free survival, which also counts deaths. The comparison was sunitinib against placebo, not bezuclastinib plus sunitinib against sunitinib.

Source: [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/); [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.5"></a>

#### 3.1.5 05-177

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Antitumor activity on a continuous schedule

> “evaluate the antitumor activity of SU011248”

Source: [Dana-Farber Cancer Institute sunitinib continuous daily dosing trial page](https://www.dana-farber.org/clinical-trials/05-177)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

No evidence found.

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Open-label phase 2 design

> “open-label phase II study”

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Histologic diagnosis and suitability for standard therapy

> “Histopathologically proven diagnosis of malignant GIST that was not amenable to standard therapy.”

Source: [Dana-Farber Cancer Institute sunitinib continuous daily dosing trial page](https://www.dana-farber.org/clinical-trials/05-177)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Summary

Participants were randomized to morning or evening administration of continuous daily sunitinib. This was a comparison of administration times, not of sunitinib against another drug.

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="topic-3.1.5.5-2"></a>

###### Continuous daily dose

> “sunitinib 37.5mg/day”

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Clinical Benefit Rate as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Summary

The primary clinical benefit rate combined complete responses, partial responses, and stable disease lasting at least 24 weeks.

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="topic-3.1.5.6.1-2"></a>

###### Primary endpoint

> “clinical benefit rate”

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="topic-3.1.5.6.1-3"></a>

###### Regulatory context for interpreting stable disease

> “Stable disease can reflect the natural history of disease, whereas tumor reduction is a direct therapeutic effect.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned and treated populations

| Population | Participants |
| --- | --- |
| Planned | “61” |
| Treated | “Sixty” |
| Per dosing-time group | “30” |

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Confidence interval accompanying the clinical benefit rate

> “95% exact CI”

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="topic-3.1.5.7.2-2"></a>

###### Detailed analysis-set definitions

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Study completion

| Disposition | Participants |
| --- | --- |
| Completed the study | “26” |

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Continuous-dosing sunitinib study

> “Median PFS was 34 weeks (95% CI, 24-49)”

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="topic-3.1.5.8.3-2"></a>

###### Clinical benefit and overall survival

| Outcome | Value |
| --- | --- |
| Clinical benefit rate | “53%” |
| Median overall survival | “107 weeks” |

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Severity of most adverse events

> “grade 1 or 2”

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The study treated 60 participants and was open-label. Randomization compared morning and evening dosing rather than continuous dosing against the intermittent schedule or against another therapy. The clinical benefit endpoint included prolonged stable disease, which is not equivalent to objective tumor response.

Source: [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/); [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.6"></a>

#### 3.1.6 PLX121-01

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Dose-finding objective

> “maximum tolerated dose/recommended phase 2 dose”

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Enrollment period

> “March 2015 through February 2019”

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Summary

The monotherapy and sunitinib-combination cohorts used nonrandomized 3+3 dose escalation.

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="topic-3.1.6.3-2"></a>

###### Blinding and dose-escalation design

> “open-label”
> “3+3”

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Age and performance-status thresholds

| Criterion | Value |
| --- | --- |
| Minimum age, years | “18” |
| ECOG performance status | “0 to 2” |

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Summary

The early-trial recommended phase 2 dose was PLX9486 1000 mg daily, combined with sunitinib 25 or 37.5 mg daily in continuous 28-day cycles.

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="topic-3.1.6.5-2"></a>

###### Recommended phase 2 dose

| Drug | Daily dose, mg |
| --- | --- |
| PLX9486 | “1000” |

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Maximum Tolerated Dose as the Primary Endpoint

Not applicable.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Unique enrolled population

| Population | Participants |
| --- | --- |
| PLX9486-naive participants | “39” |
| Participants with GIST | “35” |

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="topic-3.1.6.7.1-2"></a>

###### Combination efficacy cohort

> “Among the 15 patients”

Source: [Cogent Biosciences (2020)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-final-results-plx9486-phase-12)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Summary

Sample sizes reflected clinical considerations. Response intervals used exact binomial methods, and survival analyses used Kaplan-Meier methods.

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="topic-3.1.6.7.2-2"></a>

###### Time-to-event analysis method

> “Kaplan-Meier”

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Summary

Three monotherapy participants were reenrolled in the extension, producing a safety population of 18 without increasing unique enrollment.

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="topic-3.1.6.8.1-2"></a>

###### Combination-extension safety population

| Population | Participants |
| --- | --- |
| Including reenrolled participants | “18” |

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Baseline age and sex

| Characteristic | Value |
| --- | --- |
| Median age, years | “57” |
| Male participants, percent | “56.4%” |

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### PLX9486 plus sunitinib phase 1b/2a: efficacy

> “median progression free survival (PFS) was 12 months”
> “confirmed ORR was 20%”
> “clinical benefit rate (CR+PR+SD) was 80%”

Source: [Cogent Biosciences (2020)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-final-results-plx9486-phase-12)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Combination dose-limiting toxicity and commonly reported adverse events

> “there were no dose limiting toxicities in the three dose levels tested”
> “anemia, hypophosphatemia, diarrhea, and lymphopenia.”

Source: [Cogent Biosciences (2020)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-final-results-plx9486-phase-12)

Additional sources: [Wagner et al. (2018)](https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.11509)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

The combination efficacy cohort included 15 PLX9486-naive participants. Nonrandomized treatment assignment, small sample size, and disease heterogeneity limit comparative interpretation.

Source: [Cogent Biosciences (2020)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-final-results-plx9486-phase-12); [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="topic-3.1.6.9-2"></a>

###### Published study limitations

> “the small sample size and the heterogeneous nature of this disease limits our interpretation”

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

## Related pages
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Terms and abbreviations](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations.md)
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Product information and disease description](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: References](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses.md)
